Evidence map›Paper›PMID 41354959›Full record

ArticleJournal of nanobiotechnology2025

Tumor targeting dendritic nanocarrier with immunogenic cell death inducing and TIGIT blockade for synergistic chemo-immunotherapy against TNBC.

Jia Wang, Zhiji Wang, Kaiming Li, Yue Liu, Chunming Tang, Huimin Gao, Yupeng Zhou, Pengpeng Wang, Haisi Wu, Pengfei Liu and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jia Wang *Department of Pharmaceutics, School of Pharmacy, Nanjing Medical University, Nanjing, 211166, China.
Zhiji Wang *Department of Pharmaceutics, School of Pharmacy, Nanjing Medical University, Nanjing, 211166, China.
Kaiming LiDepartment of Pharmaceutics, School of Pharmacy, Nanjing Medical University, Nanjing, 211166, China.
Yue LiuDepartment of Geriatric Gastroenterology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.
Chunming TangDepartment of Pharmaceutics, School of Pharmacy, Nanjing Medical University, Nanjing, 211166, China.
Huimin GaoDepartment of Pharmaceutics, School of Pharmacy, Nanjing Medical University, Nanjing, 211166, China.
Yupeng ZhouDepartment of Pharmaceutics, School of Pharmacy, Nanjing Medical University, Nanjing, 211166, China.
Pengpeng WangDepartment of Pharmaceutics, School of Pharmacy, Nanjing Medical University, Nanjing, 211166, China.
Haisi WuDepartment of Pharmaceutics, School of Pharmacy, Nanjing Medical University, Nanjing, 211166, China.
Pengfei LiuDepartment of Gastroenterology, the Jiangyin Clinlcal College of Xuzhou Medical University, Jiangyin, 214400, China. pengfeimd@163.com.
Huae XuDepartment of Pharmaceutics, School of Pharmacy, Nanjing Medical University, Nanjing, 211166, China. xuhuae@njmu.edu.cn.
Xiaolin LiDepartment of Geriatric Gastroenterology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China. lxl@njmu.edu.cn.

Funding

high-level startup fund of Nanjing Medical University KY109RC2019010Joint Open Research Fund of Suzhou Institute of Nanotechnology and Nano-bionics & Jiangsu Province Hospital, the Medical Engineering Translational Fund of Jiangsu Province Hospital NM202404key research and development program of Jiangsu province BE2023834National Natural Science Foundation of China 82102737National Natural Science Foundation of China 82373105Natural Science Foundation of Jiangsu Province BK20251759Wuxi "Taihu talent plan" for excellent medical expert team Grant No. 2021-9
6 · The paper itself

Abstract

The clinical therapeutic effect of immune-checkpoint blockade (ICB) on triple-negative breast cancer (TNBC) is limited due to low tumor immunogenicity and tumor immunosuppressive microenvironment. Combination therapies of chemotherapy and ICB have been confirmed efficacious. Herein, poly(L-lysine) dendrimer (PLLD) nanosphere (PR-T@PLLD) integrating chemotherapeutic drug paclitaxel (PTX), natural anti-tumor compound Rubioncolin C (RC) and TIGIT/PVR blocking peptide

Indexed as

Drug CarriersImmunogenic Cell DeathImmunotherapyNanoparticlesReceptors, ImmunologicTriple Negative Breast NeoplasmsAnimalsAntineoplastic AgentsCell Line, TumorDendrimersDrug SynergismFemaleHumansMiceMice, Inbred BALB CPaclitaxelAntineoplastic AgentsDendrimersDrug CarriersPaclitaxelReceptors, ImmunologicTIGIT protein, humanChemo-immunotherapyImmunogenic cell deathPoly(L-lysine) dendrimerTIGIT/PVR blockadeTumor immunosuppressive microenvironment

Identifiers

PMID41354959
PMCPMC12683850

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.